Login to Your Account

BioCryst, Presidio 'Nuc' Tie; Plans Flu HAE but Fell Far

By Randy Osborne
Staff Writer

Monday, December 3, 2012
Investors must wait until a conference call later this week for full details, but the decision by BioCryst Pharmaceuticals Inc. and Presidio Pharmaceuticals Inc. to ditch their $101 million merger might seem almost inevitable, coming in the wake of problems for BioCryst's drug candidates in flu, hepatitis C virus (HCV) and hereditary angioedema.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription